- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02363322
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Background:
- Ebola is a viral infection that can spread quickly and causes life-threatening disease. Right now there is an Ebola outbreak in many countries in West Africa. There are no approved treatments for Ebola. But possible treatments are being developed. Researchers need to study these treatments to see if they help people get better.
Objective:
- To identify possible Ebola treatments. Also, to learn if adding 1 or more experimental drugs to advanced Ebola care can reduce the risk of death.
Eligibility:
- People who have recently been diagnosed with Ebola, usually by a test called the Polymerase Chain Reaction (PCR), and have been hospitalized in an isolation unit for treatment.
Design:
- Participants will be randomly assigned to Group A or B. Both groups will get advanced level care. One group will also get an experimental drug.
- Participants may have blood tests. They may have another PCR test.
- Researchers will try to learn how the participant got Ebola.
- Participants put in the experimental drug group may start taking medicine within 24 hours of enrollment. It may be given by mouth or intravenously. Additional doses may be needed.
- Participants may have a series of timed blood tests over the first 24 to 48 hours after they take the medicine.
- Blood will be drawn frequently. Other body fluids (urine, stool, vaginal fluid, etc.) may also be collected.
- Participants will be followed for up to 60 days. They may be evaluated for any long-term effects of the experimental treatment(s). They may be asked to return for 1 or more outpatient visits.
- For consenting participants, follow-up will be extended for up to one full year past Day 58 with contact/visits every 1-3 months to assess for a history of signs or symptoms potentially consistent with late onset of virologic relapse syndrome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ebolaviruses (EBOV) are members of the Filoviridae and are known primarily as the underlying cause of severe viral hemorrhagic fevers with disturbingly high case fatality rates. Between 1994 and the present, there have been many EBOV outbreaks affecting mostly central Africa, with 2 large outbreaks in 1995 in Kikwit, Democratic Republic of Congo (DRC), and in Gulu, Uganda in 2000-2001. However, the 2014 West African outbreak significantly exceeds all previous outbreaks in geographic range, number of patients affected, and in disruption of typical activities of civil society.
There is strong consensus that the most important element necessary to improve survival from Ebola infection is the provision of full hemodynamic support in the form of aggressive fluid replacement, ability to diagnose and correct severe metabolic derangements, and other standards of modern medical care available in resource-rich environments. However, against this background, a small series of investigational agents or interventions have also been proposed as putative antiviral strategies of potential utility in treating this infection. Unfortunately, phase 1/2 data supporting the safety and efficacy of these agents is generally lacking, and thus there should be equipoise as to which, if any, of these interventions should be utilized in the treatment of severe infection.
In this multicenter randomized trial, we propose a flexible trial design with frequent interim monitoring to facilitate early elimination of poorly performing treatments as well as the introduction of new candidate therapies. The trial allows for a series of pairwise comparisons of novel interventions against a background of optimized medical care, with the goal of determining whether one or more of these interventions can improve the mortality over that achievable through optimized standard-of- care (oSOC) alone. The primary endpoint of this trial will be comparative mortality at Day 28, with a number of secondary endpoints that hopefully will generate generalizable knowledge about the relative safety and antiviral activity of these adjunctive interventions.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Forecariah, Guinea
- CTE Forecariah
-
-
-
-
-
Monrovia, Liberia
- Monrovia Medical Unit
-
Paynesville, Liberia
- ELWA III Hospital
-
-
-
-
-
Freetown, Sierra Leone
- Police Training School 1 (PTS1), Western Rural District
-
Goderich, Sierra Leone
- Emergency Ebola Treatment Unit
-
Hastings, Sierra Leone
- Police Training School 2
-
Jui, Sierra Leone
- Chinese Friendship Hospital
-
Kambia, Sierra Leone
- International Medical Corps (IMC) Kambia
-
Port Loko, Sierra Leone
- International Medical Corps (IMC) Lunsar
-
Waterloo, Sierra Leone
- Adventist Development and Relief Ebola Treatment Unit
-
-
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
- Males or females with documented positive PCR for Ebola virus infection within 10 days of enrollment
- Willingness of study participant to accept randomization to any assigned treatment arm
- Access to oSOC
- All males and females of childbearing potential, must be willing to use highly effective methods of contraception [e.g. absolute abstinence from potentially reproductive sexual activity, hormonal, surgical or multiple barrier/combined], from time of enrollment for the duration of study participation.
- Must agree not to enroll in another study of an investigational agent prior to completion of last required protocol visit (Day 58)
- Ability to provide informed consent personally, or by a legally-authorized [per applicable local laws and regulations] representative [LAR] if the patient is unable to do so.
EXCLUSION CRITERIA:
- Any medical condition that, in the opinion of the site investigator, would place the patient at an unreasonably increased risk through participation in this study, including any past or concurrent conditions that would preclude randomization to one or more of the assigned treatment arms.
- Prior treatment with any investigational antiviral drug therapy against Ebola infection other than experimental vaccines, within 5 half-lives or 30 days, whichever is longer, prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A/Current Standard of Care Alone
A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
|
Optimized standard of care for Ebola virus infection
|
Experimental: B/Current Standard of Care Plus ZMapp
B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting. ZMapp 50mg/kg IV administered every third day for 3 infusions. |
Optimized standard of care for Ebola virus infection
Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 28 days
|
Death at Day 28
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With ZMapp Infusion-related Adverse Events
Time Frame: 10 Days
|
Adverse events related to ZMapp infusions
|
10 Days
|
Plasma Viral Load
Time Frame: 28 days
|
Time to viral clearance
|
28 days
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA. 2014 Oct 1;312(13):1299-300. doi: 10.1001/jama.2014.12867. No abstract available.
- Kanapathipillai R. Ebola virus disease--current knowledge. N Engl J Med. 2014 Sep 25;371(13):e18. doi: 10.1056/NEJMp1410741. No abstract available.
- Piot P, Muyembe JJ, Edmunds WJ. Ebola in west Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis. 2014 Nov;14(11):1034-1035. doi: 10.1016/S1473-3099(14)70956-9. Epub 2014 Oct 1. No abstract available.
- PREVAIL II Writing Group; Multi-National PREVAIL II Study Team; Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016 Oct 13;375(15):1448-1456. doi: 10.1056/NEJMoa1604330.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 150083
- 15-I-0083 (Other Identifier: NIH Office of Protocol Services)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ebola Virus Infection
-
Arbutus Biopharma CorporationUnited States Department of DefenseTerminatedEbola Virus InfectionUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Arbutus Biopharma CorporationUnited States Department of DefenseTerminatedEbola Virus InfectionUnited States
-
BioCryst PharmaceuticalsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedEbola Virus Infection | Filovirus InfectionsUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Hemorrhagic Fever | Ebola Virus Vaccines | Envelope Glycoprotein, Ebola Virus | FilovirusUnited States
-
Institute of Tropical Medicine, BelgiumWorld Health Organization; Institut National de Recherche Biomédicale. Kinshasa... and other collaboratorsTerminatedEbola Virus Disease | Bloodstream Infection | Sepsis BacterialCongo, The Democratic Republic of the
-
National Institute of Allergy and Infectious Diseases...Completed
-
Institut National de la Santé Et de la Recherche...TerminatedEbola Virus SurvivorGuinea
-
Makerere UniversityMRC/UVRI and LSHTM Uganda Research Unit; Ministry of Health, Uganda; Epicentre; Makerere University Lung Institute and other collaboratorsNot yet recruitingSudan Ebola Virus Vaccines
-
National Institute of Allergy and Infectious Diseases...CompletedEbola VirusUnited States, Congo, The Democratic Republic of the
Clinical Trials on A/Current Standard of Care Alone
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
National Institute of Dental and Craniofacial Research...CompletedHealthy | Tooth DiseaseUnited States
-
National Eye Institute (NEI)Completed
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)Completed
-
Children's National Research InstituteGeorgetown UniversityCompletedAutism Spectrum DisorderUnited States
-
Maastricht University Medical CenterNot yet recruitingAtrial Fibrillation | Pacemaker DDD | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Permanent Atrial Fibrillation
-
Portsmouth Hospitals NHS TrustUniversity of PortsmouthCompletedIntestinal Neoplasms | Digestive System Disease | Gastrointestinal Disease | Colorectal Neoplasia | Intestinal Disease | Gastrointestinal Neoplasm | Digestive NeoplasmsUnited Kingdom
-
Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-HessenNHS Blood and TransplantRecruitingCOVID-19Germany, France, Netherlands, United Kingdom
-
DIApedia, LLCNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes | Plantar Ulcer | Neuropathy Causing Loss of Protective SensationUnited States
-
Huntleigh Healthcare LtdSerenaGroup, Inc.Completed